# Ceftriaxone for Post-Treatment Lyme Disease

> **NCT06785402** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Hackensack Meridian Health**

## Conditions studied

- Post-Treatment Lyme Disease Syndrome

## Interventions

- **DRUG:** Ceftriaxone treatment
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06785402
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-05-14
- **Primary completion:** 2026-05-14
- **Final completion:** 2026-05-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Enrollment challenges
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06785402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06785402, "Ceftriaxone for Post-Treatment Lyme Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06785402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*